2020 operating cash burn is expected to be at the low end of the prior guidance range of $220-230M due to one-quarter delay (to 3Q20) in the US launch of Teoxane’s dermal fillers.
MYL’s decision whether to opt in for the Botox-biosimilar program is expected by the end of May.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”